Once-weekly (70 mg/m2) versus twice-weekly (56 mg/m2) dosing of carfilzomib (CFZ) for patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).

Philippe Moreau,A. Keith Stewart,Meletios A. Dimopoulos,David Samuel DiCapua Siegel,Thierry Facon,James R. Berenson,Noopur S. Raje,Jesus G. Berdeja,Robert Z. Orlowski,Hui Yang,Haijun Ma,Zandra Karina Klippel,Anita Zahlten-Kumeli,Khalid Mezzi,Karim Iskander,Maria-Victoria Mateos

Journal of Clinical Oncology（2019）

引用 0|浏览47

暂无评分

摘要

e19505Background: CFZ combined with dexamethasone is approved to treat pts with RRMM, with CFZ given once-weekly at 70 mg/m2 (Kd70 QW) or twice-weekly at 56 mg/m2 (Kd56 BIW). No randomized trials h...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要